11,195 Johnson & Johnson $JNJ Shares Sold by Cornerstone Advisors LLC

Cornerstone Advisors LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 157,591 shares of the company’s stock after selling 11,195 shares during the period. Johnson & Johnson comprises approximately 1.4% of Cornerstone Advisors LLC’s portfolio, making the stock its 14th largest position. Cornerstone Advisors LLC’s holdings in Johnson & Johnson were worth $41,721,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. 10Elms LLP boosted its holdings in Johnson & Johnson by 6.8% during the 3rd quarter. 10Elms LLP now owns 1,263 shares of the company’s stock valued at $334,000 after acquiring an additional 80 shares during the period. Aberdeen Group plc grew its position in Johnson & Johnson by 8.5% during the 3rd quarter. Aberdeen Group plc now owns 2,654,448 shares of the company’s stock worth $702,739,000 after acquiring an additional 207,390 shares during the last quarter. Stonebridge Financial Planning Group LLC increased its stake in Johnson & Johnson by 2.6% in the 3rd quarter. Stonebridge Financial Planning Group LLC now owns 2,529 shares of the company’s stock worth $670,000 after purchasing an additional 64 shares during the period. Valmark Advisers Inc. increased its stake in Johnson & Johnson by 1.0% in the 3rd quarter. Valmark Advisers Inc. now owns 23,840 shares of the company’s stock worth $6,311,000 after purchasing an additional 232 shares during the period. Finally, PFC Capital Group Inc. lifted its position in Johnson & Johnson by 3.4% in the third quarter. PFC Capital Group Inc. now owns 11,167 shares of the company’s stock valued at $2,956,000 after purchasing an additional 367 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 13,072 shares of the business’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. The trade was a 43.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 61,669 shares of company stock valued at $16,898,386 over the last quarter. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Up 0.8%

Shares of NYSE:JNJ opened at $285.78 on Friday. The stock’s 50-day moving average is $266.97 and its 200 day moving average is $249.85. The company has a market cap of $687.95 billion, a PE ratio of 43.30, a P/E/G ratio of 2.80 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. Johnson & Johnson has a 1 year low of $193.55 and a 1 year high of $288.11.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the business posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Key Headlines Impacting Johnson & Johnson

These are some of the JNJ headlines that stood out recently:

• Positive Sentiment: A Johnson & Johnson prostate-cancer drug combination is advancing into Phase 3, a meaningful clinical milestone that could strengthen the company’s oncology pipeline, although trial and commercial outcomes remain uncertain. Johnson & Johnson stock advances as prostate drug combo enters Phase 3
• Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
• Neutral Sentiment: J&J also led a $100 million funding round for Delix Therapeutics’ depression-drug development. This broadens its exposure to emerging psychiatric treatments, but clinical-stage programs carry substantial execution risk. Johnson & Johnson Backs New Cancer Device And Leads $100 Million Depression Bet

Analyst Ratings Changes

A number of analysts have recently weighed in on JNJ shares. TD Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 14th. Weiss Ratings lowered shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. Johnson Rice cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Finally, Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.